CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,952 | +57.3% | 175,188 | +94.6% | 0.07% | +64.4% |
| Q2 2023 | $5,054 | +19.5% | 90,030 | -3.8% | 0.04% | +18.4% |
| Q1 2023 | $4,231 | +244.8% | 93,539 | +209.9% | 0.04% | +245.5% |
| Q4 2022 | $1,227 | -99.9% | 30,179 | -6.7% | 0.01% | -56.0% |
| Q3 2022 | $2,112,000 | -17.8% | 32,329 | -23.5% | 0.02% | -10.7% |
| Q2 2022 | $2,569,000 | +118.8% | 42,274 | +126.2% | 0.03% | +154.5% |
| Q1 2022 | $1,174,000 | +67.5% | 18,692 | +102.0% | 0.01% | +83.3% |
| Q4 2021 | $701,000 | -67.5% | 9,253 | -52.0% | 0.01% | -73.9% |
| Q3 2021 | $2,160,000 | +33.7% | 19,293 | +93.3% | 0.02% | +43.8% |
| Q2 2021 | $1,616,000 | – | 9,983 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |